House Energy and Commerce hearing spotlights Medicare coverage for multicancer early‑detection tests

At a House Energy and Commerce subcommittee hearing, members and witnesses debated H.R. 842, the Nancy Gardner Sewell Medicare Multicancer Early Detection Screening Coverage Act, which would give the Centers for Medicare & Medicaid Services (CMS) an authority-based pathway to evaluate whether to cover FDA‑authorized blood-based multicancer early detection tests for Medicare beneficiaries.

The bill’s supporters said the tests, which analyze circulating tumor DNA from a blood draw, could detect many cancers earlier than current, organ‑specific screening programs and therefore save lives and money. Steven Ezell, vice president of global innovation policy at the Information Technology and Innovation Foundation, said, “Cancer claims over 600,000 American lives annually,” and argued that MCED tests can expand screening beyond the five cancers now commonly screened for.

Why it matters: Seniors account for most U.S. cancer diagnoses and cancer care consumes substantial Medicare dollars; lawmakers said…